Sabina Mugusi
Sabina Mugusi
Muhimbili University of Health and Allied Sciences
Verified email at
Cited by
Cited by
Long‐term efavirenz autoinduction and its effect on plasma exposure in HIV patients
E Ngaimisi, S Mugusi, OM Minzi, P Sasi, KD Riedel, A Suda, N Ueda, ...
Clinical Pharmacology & Therapeutics 88 (5), 676-684, 2010
Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa …
E Ngaimisi, A Habtewold, O Minzi, E Makonnen, S Mugusi, W Amogne, ...
PloS one 8 (7), e67946, 2013
Effect of Rifampicin and CYP2B6 Genotype on Long‐Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis
E Ngaimisi, S Mugusi, O Minzi, P Sasi, KD Riedel, A Suda, N Ueda, ...
Clinical Pharmacology & Therapeutics 90 (3), 406-413, 2011
Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania
S Mugusi, E Ngaimisi, M Janabi, O Minzi, M Bakari, KD Riedel, ...
PloS one 7 (7), e40180, 2012
Enhancing adherence to antiretroviral therapy at the HIV clinic in resource constrained countries; the Tanzanian experience
F Mugusi, S Mugusi, M Bakari, B Hejdemann, R Josiah, M Janabi, ...
Tropical Medicine & International Health 14 (10), 1226-1232, 2009
β-defensin genomic copy number is associated with HIV load and immune reconstitution in sub-saharan Africans
RJ Hardwick, W Amogne, S Mugusi, G Yimer, E Ngaimisi, A Habtewold, ...
The Journal of infectious diseases 206 (7), 1012-1019, 2012
Frequency of the SLCO1B1 388A> G and the 521T> C polymorphism in Tanzania genotyped by a new LightCycler®-based method
E Aklillu, S Mugusi, E Ngaimisi, MM Hoffmann, S König, V Ziesenitz, ...
European journal of clinical pharmacology 67 (11), 1139-1145, 2011
CCL3L1 copy number, HIV load, and immune reconstitution in sub-Saharan Africans
E Aklillu, L Odenthal-Hesse, J Bowdrey, A Habtewold, E Ngaimisi, ...
BMC infectious diseases 13 (1), 1-10, 2013
Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment
E Ngaimisi, O Minzi, S Mugusi, P Sasi, KD Riedel, A Suda, N Ueda, ...
Journal of Antimicrobial Chemotherapy 69 (12), 3311-3319, 2014
Effect of improved access to antiretroviral therapy on clinical characteristics of patients enrolled in the HIV care and treatment clinic, at Muhimbili National Hospital (MNH …
SF Mugusi, JC Mwita, JM Francis, S Aboud, M Bakari, EA Aris, AB Swai, ...
BMC Public Health 10 (1), 1-7, 2010
SLCO1B1 Gene Variations Among Tanzanians, Ethiopians, and Europeans: Relevance for African and Worldwide Precision Medicine
E Aklillu, A Habtewold, E Ngaimisi, G Yimer, S Mugusi, W Amogne, ...
Omics: a journal of integrative biology 20 (9), 538-545, 2016
Copy number variation of Fc gamma receptor genes in HIV-infected and HIV-tuberculosis co-infected individuals in sub-Saharan Africa
LR Machado, J Bowdrey, E Ngaimisi, A Habtewold, O Minzi, E Makonnen, ...
PloS one 8 (11), e78165, 2013
Risk factors for mortality among HIV-positive patients with and without active tuberculosis in Dar es Salaam, Tanzania.
SF Mugusi, E Ngaimisi, MY Janabi, FM Mugusi, O Minzi, PG Sasi, ...
Antiviral therapy 17 (2), 265-74, 2012
Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second …
J Svärd, S Mugusi, D Mloka, U Neogi, G Meini, F Mugusi, F Incardona, ...
PloS one 12 (6), e0178942, 2017
Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin
S Mugusi, E Ngaimisi, M Janabi, F Mugusi, O Minzi, E Aris, M Bakari, ...
European journal of clinical pharmacology 74 (11), 1405-1415, 2018
Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/tuberculosis patients with the same CYP2B6* 6 genotype
EN Kitabi, OMS Minzi, S Mugusi, P Sasi, M Janabi, F Mugusi, L Bertilsson, ...
Scientific reports 8 (1), 1-12, 2018
Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort …
S Mugusi, A Habtewold, E Ngaimisi, W Amogne, G Yimer, O Minzi, ...
Frontiers in pharmacology 11, 26, 2020
Adherence to combination antiretroviral therapy among orphaned children in Dar es Salaam, Tanzania
SF Mugusi, N Mopei, O Minzi
Southern African journal of HIV medicine 20 (1), 1-8, 2019
Optimization of HIV and tuberculosis co-treatment in Tanzania: drug-drug interactions and clinical outcomes
S Mugusi
Inst för klinisk forskning och utbildning, Södersjukhuset/Dept of Clinical …, 2013
A Comparison of Patients on First Line and Second Line Antiretroviral Therapy in Dar es Salaam, Tanzania
GA Shayo, FB Seleki, SF Mugusi, FM Mugusi
Tanzania Medical Journal 31 (4), 77-92, 2020
The system can't perform the operation now. Try again later.
Articles 1–20